Keyphrases
Advanced Malignancies
100%
Phase I Study
100%
Gemcitabine
100%
Rubitecan
100%
Maximum Tolerated Dose
40%
Diarrhea
20%
Neutropenia
20%
Dose-limiting Toxicity
20%
Dose Escalation
20%
Ovarian Carcinoma
20%
Intravenous Infusion
20%
Thrombocytopenia
20%
Stable Disease
20%
Nausea-vomiting
20%
Dose-escalation Trial
20%
Refractory Malignancy
20%
Myelosuppression
20%
Pancreatic Carcinoma
20%
Agent Behavior
20%
Subsequent Malignancies
20%
Recommended Phase 2 Dose
20%
Phase I Trial
20%
9-Nitrocamptothecin
20%
Medicine and Dentistry
Cancer
100%
Gemcitabine
100%
Rubitecan
100%
Neutropenia
14%
Diarrhea
14%
Intravenous Drug Administration
14%
Krukenberg Tumor
14%
Thrombocytopenia
14%
Side Effect
14%
Isoprenaline
14%
Bone Marrow Suppression
14%
Pancreas Carcinoma
14%
Nausea and Vomiting
14%
Phase I Trials
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
100%
Rubitecan
100%
Maximum Tolerated Dose
28%
Diarrhea
14%
Neutropenia
14%
Side Effect
14%
Thrombocytopenia
14%
Isoprenaline
14%
Bone Marrow Suppression
14%
Ovary Carcinoma
14%
Nausea and Vomiting
14%
Pancreas Carcinoma
14%
Phase I Trials
14%
Diseases
14%